Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library

N-of-1 self-tracking and observational registries: what they can and cannot show

Name: N-of-1 self-tracking and observational registries: what they can and cannot show
Published: 2026-10-27

How baselines, washouts and validated questionnaires make self-reported data more useful, and why they still cannot replace blinded trials

Evidence verdict: Based on methods research on blinding, placebo and N-of-1 trials, and on the published Open Peptide registry protocol. A methods explainer, not a product rating. [1, 2, 4, 7]

Last reviewed: Oct 27, 2026

In 30 seconds

When people know what they are taking, subjective outcomes such as pain, energy or sleep tend to look better than they really are. Objective measures are much less affected. [1, 2] [Controlled study, meta-epidemiology]
Regression to the mean and natural ups and downs can look like a treatment effect, especially when people start something on a bad day. [3] [Methods]
A baseline period, a washout, and validated questionnaires such as PROMIS make self-tracking more consistent, but they do not remove bias. [4, 5, 6] [Methods, Policy]
The Open Peptide registry is self-reported, unblinded and self-selected. Its results describe experiences and can suggest questions for trials; they cannot show that a peptide works. [7] [Policy]

Why self-reports mislead

In a large study of meta-analyses, trials without proper blinding exaggerated treatment effects for subjective outcomes (ratio of odds ratios 0.75), with little bias for objective outcomes such as death. [1] [Controlled study, meta-epidemiology] Outcome assessors who knew who got the treatment exaggerated odds ratios by 36% on average. [2] [Controlled study, meta-epidemiology] A Cochrane review found placebo had no important effects in general, but possible effects on patient-reported outcomes, especially pain and nausea. [8] [Controlled study, systematic review] Self-tracking a peptide you chose, bought and expect to help is the least blinded situation possible.

Regression to the mean and natural variation

People tend to start something new when symptoms are at their worst. Symptoms that fluctuate will often drift back toward their usual level anyway, which looks like improvement. This statistical effect, regression to the mean, can create an apparent change with no treatment effect at all. [3] [Methods]

What a formal N-of-1 trial adds

A formal N-of-1 trial tests treatment in one person across repeated, ideally randomized and blinded, periods on and off treatment, with washouts in between. The CENT 2015 statement sets reporting standards for these trials, including how periods, washouts and blinding are described. [4] [Methods] Most informal self-tracking has none of those protections.

Using validated measures

PROMIS (Patient-Reported Outcomes Measurement Information System) item banks are questionnaires built and tested to measure symptoms such as fatigue, sleep and physical function consistently. [5] [Methods] Using a validated, repeatable measure is more reliable than an ad hoc 1-to-10 rating, but it is still self-report and still affected by expectation.

How the Open Peptide registry is designed

The registry protocol asks participants to record a 14-day pre-start baseline, and current users to complete a washout of at least 4 weeks before a new baseline. Each person's baseline serves as their own comparison. [6, 7] [Policy] Outcomes use PROMIS Global Health-10 and PROMIS Sleep 4a, with the Patient-Specific Functional Scale (PSFS) as the primary outcome. [6] [Policy] Entries are tiered by whether the batch used was verified by blind testing, declared, or unverified. [6] [Policy] The registry states its limits up front: it is self-reported, unblinded and self-selected. [7] [Policy] It collects observations; it does not give anyone instructions on what to take.

What registry data can and cannot do

Registry data can show which effects and side effects people report, how often, and which questions are worth a proper trial. They cannot establish that a peptide works, how well it works, or that it is safe, because they lack randomization, blinding and a control group. [1, 7] [Controlled study, Policy] See the guide on evaluating human vs. rodent studies for how the evidence grades on this site are set.

Evidence levels used on this page

[Regulatory] FDA, USP or WADA primary document or an FDA-approved label. [Controlled study] randomized trial or systematic review of trials. [Observational] surveillance, pharmacovigilance or cohort data. [Lab] analytical, cell or animal work. [Guidance] professional-society guidance. [Policy] Open Peptide Project published policy.

Open Peptide registry, Registry protocol, How to evaluate human vs. rodent peptide studies

References

Barnett AG, et al. Regression to the mean: what it is and how to deal with it. Int J Epidemiol. 2005. PMID 15333621.
Hróbjartsson A, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ. 2012. PMID 22371859.
Cella D, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010. PMID 20685078.
Vohra S, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015 statement. BMJ. 2015. PMID 25976398.
Wood L, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008. PMID 18316340.
Open Peptide Project. Registry protocol, read Oct 27, 2026. https://openpeptideproject.org/protocol/
Open Peptide Project. Registry, read Oct 27, 2026. https://openpeptideproject.org/registry/
Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. 2010. PMID 20091554.

Disclaimer: This page is for education only. It is not medical advice, and it does not endorse using, buying or preparing any unapproved product. Talk to a licensed clinician before you start, stop or change any treatment.